RaNA Therapeutics is an innovative and rapidly-expanding biotechnology company. Through in vivo and in vitro experiments, our scientists are developing novel therapeutics that have the potential to provide better treatment for a large number of diseases influenced by epigenetic patterns. Our technology is based on research performed by Jeannie T. Lee, MD, PhD, at Massachusetts General Hospital. Dr. Lee and colleagues discovered thousands of long non-coding RNA's that contain binding regions for epigenetic regulatory proteins. By blocking the binding of one such regulatory complex, PCR2, to individual lncRNA regions, we can induce the expression of individual targeted genes and thereby restore normal protein functioning.